Biogen Announces Two New Nominees for Election to Board of Directors biospace.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from biospace.com Daily Mail and Mail on Sunday newspapers.
Biogen Announces Two New Nominees for Election to Board of Directors
April 09, 2021 16:30 ET | Source: Biogen Inc. Biogen Inc. Cambridge, Massachusetts, UNITED STATES
Nominees bring diverse business and public health experience key to Biogen’s mission to pioneer and lead in neuroscience
Company thanks Director Robert W. Pangia as he retires from the Board
CAMBRIDGE, Mass., April 09, 2021 (GLOBE NEWSWIRE) Biogen Inc. (Nasdaq: BIIB) today announced the nomination of Maria C. Freire, Ph.D. and William D. Jones to stand for election to the company’s board of directors at its 2021 annual meeting of stockholders, scheduled for June 2, 2021. Additionally, Robert W. Pangia, who has served on the board since 1997 and is Chair of the Compensation and Management Development Committee, will retire from the company’s board this year, effective at the annual meeting of stockholders.
Biogen Inc.: Biogen Announces Two New Nominees for Election to Board of Directors
Company thanks Director Robert W. Pangia as he retires from the Board
CAMBRIDGE, Mass., April 09, 2021(Nasdaq: BIIB) today announced the nomination of Maria C. Freire, Ph.D. and William D. Jones to stand for election to the company s board of directors at its 2021 annual meeting of stockholders, scheduled for June 2, 2021. Additionally, Robert W. Pangia, who has served on the board since 1997 and is Chair of the Compensation and Management Development Committee, will retire from the company s board this year, effective at the annual meeting of stockholders.
Dr. Freire is President and Executive Director and member of the board of directors of the Foundation for the National Institutes of Health, a nonprofit organization committed to accelerating biomedical research and advancing breakthrough discoveries to fight critical diseases. Mr. Jones is the President and Chief Executive Officer and a director
Tuesday, March 2, 2021
NIH invests in next iteration of public-private partnership to advance precision medicine research for Alzheimerâs disease
The National Institutes of Health has launched the next version of the Accelerating Medicines Partnership (AMP) Alzheimerâs disease program (AMP AD 2.0) to expand the open science, big data approach for identifying biological targets for therapeutic intervention. AMP AD 2.0 is supporting new technologies, including cutting-edge, single-cell profiling and computational modeling, to enable a precision medicine approach to therapy development. Managed through the Foundation for the NIH (FNIH), AMP AD 2.0 brings together NIH, industry, non-profit and other organizations with a shared goal of using open science practices to accelerate the discovery of new drug targets, biomarkers and disease subtypes.